Lanthanum Carbonate Is an Effective Hypophosphatemic Agent for Hemodialysis Patients Intolerant of Other Phosphate Binders

Journal of Renal Nutrition

Volumn 20, Issue 4, 2010, Pages 270-277

  Winnie Chan, Wing Lam ^a   Rounsley, Karen ^a   Chapman, Emma ^a   Collings, Katherine ^a   Dale, Clare ^a   De Waal, Susan ^a   Patel, Vandhana ^a   Tanner, Jill ^a   Turner, Elaine ^a   Moore, Jason ^a   Borrows, Richard ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943010093     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2009.10.009     Document Type: Article

References (15)

1. Kalpakian, M.A., Mehrotra, R., Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial 20 (2007), 139–143.
2. Mehrotra, R., Martin, K.J., Fishbane, S., Sprague, S.M., Zeig, S., Angel, M., Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 3 (2008), 1437–1445.
3. National Kidney Foundation, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:Suppl (2003), S1–S201.
4. Sprogue, S.M., A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin 23 (2007), 3167–3175.
5. Goodman, W.G., Goldin, J., Kuizon, B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000), 1478–1483.
6. Hercz, G., Pei, Y., Greenwood, C., et al. Aplastic osteodystrophy without aluminium: the role of “suppressed” parathyroid function. Kidney Int 44 (1993), 860–866.
7. Raggi, P., Bommer, J., Chertow, G.W., Valvular calcification in haemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 13 (2004), 134–141.
8. Suki, W.N., Zabaneh, R., Cangiano, J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in haemodialysis patients. Kidney Int 72 (2007), 1130–1137.
9. Tomasello, S., Dhupar, S., Sherman, R.A., Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Dial Transplant 33 (2004), 236–240.
10. Finn, W.F., Joy, M.S., Hladlik, G., Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving haemodialysis. Clin Nephrol 62 (2004), 193–201.
11. Joy, M.S., Finn, W.F., Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphataemia. Am J Kidney Dis 42 (2003), 96–107.
12. Finn, W.F., Lanthanum carbonate versus standard therapy for the treatment of hyperphosphataemia: safety and efficiency in chronic maintenance haemodialysis patients. Clin Nephrol 65 (2006), 191–202.
13. Hutchison, A.J., Maes, B., Vanwalleghem, J., et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 102 (2006), c61–c71.
14. Clinical Practice Guidelines for Haemodialysis. United Kingdom Renal Association, United Kingdom; 4th ed, 2007.
15. Salusky, I.B., A new era in phosphate binder therapy: what are the options?. Kidney Int 70:Suppl (2006), S10–S15.